App-Quantinova.ai

Locoregional relapse in BRCA1/2 breast cancer women treated with breast-conserving surgery.

Maria Jose Juan Fita - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.

Neda Stjepanovic - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

The 2016 Li-Fraumeni syndrome cancer spectrum.

Olivier Caron - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.

Sarina Anne Piha-Paul - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.

Eric R Gamazon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cisplatin

Contribution of the TP53 R337H mutation to the cancer burden in families with a proband with adrenocortical tumor.

Maria Jose Mastellaro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TP53

The identification of novel genetic risk loci in uveal melanoma.

Tomas Kirchhoff - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

First things first: Prevention, screening or care?

Francois Eisinger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Mibefradil

Meta-analysis of hepatocellular carcinoma incidence in patients who have obtained a sustained virologic response after antiviral therapy for hepatitis C.

Ali Hosni - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Solid malignancies

N/A

Risk of male breast cancer in users of testosterone 5 reductase inhibitors.

Hakan Lars Olsson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.

Gianpiero Fasola - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

One stop screening for multiple cancer types: 10 year experience of an integrated cancer prevention center.

Nadir Arber - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Use and adherence to breast cancer risk-reduction agents: A population-based study.

Mariana Chavez-Mac Gregor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Raloxifene

Extrahepatic cancer risk among patients with liver cirrhosis in Taiwan: A nationwide population-based study.

Chia-Jen Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

N/A

A model for predicting individualized absolute risk of contralateral breast cancer.

Marzana Chowdhury - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Are racial differences in obesity and insulin resistance related to aggressive breast cancer?

Emily Gallagher - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Risk of arterial thromboembolism in patients with colorectal cancer.

Babak B. Navi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Solid malignancies

N/A

Rethinking the Hispanic advantage in cancer outcomes: Influence of birthplace.

Paulo Pinheiro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Lung cancer risk, diabetes, and diabetes treatments.

Alice Koechlin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluating genetic and genomic sequencing knowledge from parents and young adult cancer survivors.

Trisha Ali-Shaw - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts